-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
.
.
According to data from Minet.
com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.
.
.
At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
Data source: Minet database
On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
.
.
According to data from Minet.
com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.
.
.
At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
Data source: Minet database
On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
.
Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
.
Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
.
.
According to data from Minet.
com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
hospital hospital hospitalcom, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
.
Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.
.
enterprise enterprise enterprise.
At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
, Ltd.
, has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
and Suzhou Erye Pharmaceutical
.
Data source: Minet database